Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarcoma
This Phase I clinical trial is looking at a new treatment approach for people with metastatic soft tissue sarcoma, meaning cancer that has spread from where it first started. The study is testing an experimental immunotherapy drug known as MEDI5752 alongside a precise type of radiation called stereotactic radiotherapy. Immunotherapy helps the body's natural immune system recognise and attack cancer cells, while stereotactic radiotherapy delivers targeted, high-dose radiation directly to tumours. Doctors want to find out how safe this combination is, what side effects it might cause, and the best dose to give. The study is open to adults aged 18 and over. Because it is an early-stage trial, researchers are primarily checking safety, but they will also monitor whether the treatment helps shrink tumours or stop them from growing.
At a glance
What is this study about?
Soft tissue sarcomas are rare cancers that develop in supporting tissues like muscles, fat, nerves, and blood vessels. When sarcoma spreads to other parts of the body, it is called metastatic cancer. In these cases, standard treatments do not always work well, which is why researchers are actively searching for new and more effective options.
This trial is testing an experimental drug called MEDI5752 combined with stereotactic radiotherapy. Stereotactic radiotherapy uses specialised machines to aim high doses of radiation at tumours with pinpoint accuracy. The drug, MEDI5752, is a type of immunotherapy. It is designed to take the 'brakes' off the immune system so your own body can better target and destroy cancer cells.
Researchers believe that combining focused radiation with immunotherapy might work better than either treatment on its own. The radiation may damage the cancer cells in a way that helps the immune system spot them more easily. The main goal of this early study is to see how safe the combination is, find the right dose, and check if it shows promise in controlling cancer growth.
Key takeaways
- This study tests a new drug (MEDI5752) alongside focused radiotherapy for metastatic soft tissue sarcoma.
- The primary aim is to test safety, check side effects, and find the best dose.
- It is open to adults aged 18 and older who meet specific health checks.
- Taking part involves regular hospital visits for drug infusions, radiation, and safety monitoring.
- Participation is entirely voluntary, and you can withdraw at any time.
Who may be eligible?
This clinical trial is designed for adults aged 18 or older who have been diagnosed with metastatic soft tissue sarcoma. Because it is an early trial, participants usually need to be well enough to carry out daily activities and have cancer that can be safely measured and treated with targeted radiation.
People will need to have their general health checked before taking part. This usually includes blood tests and heart checks to make sure your organs are working well enough to handle the trial treatment safely.
You may not be eligible if you have certain active medical conditions, such as severe autoimmune diseases, uncontrolled infections, or if you are pregnant or breastfeeding. The trial team will review your full medical history to decide if the study is safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with soft tissue sarcoma that has spread (metastatic).
- I am generally well enough to walk around and manage my daily self-care.
- I am willing to travel to the study hospital for regular visits and scans.
- I am not currently pregnant or breastfeeding.
What does participation involve?
If you decide to take part, you will first attend a screening visit where doctors will perform scans, blood tests, and physical exams to ensure the study is safe for you. If you join, you will receive the study drug, MEDI5752, usually given through a drip into a vein (intravenously) at regular hospital visits, alongside scheduled sessions of targeted radiotherapy.
Throughout the study, you will need to attend the clinic frequently for monitoring, blood tests, and scans to track how your cancer responds and check for side effects. You will also be asked about how you are feeling day-to-day. After finishing active treatment, you will enter a follow-up period so doctors can keep checking your health over several months or longer.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is a Phase I trial?
A Phase I trial is one of the earliest stages of human research. It focuses mainly on finding out if a new treatment is safe, what side effects it causes, and determining the correct dose.
How is stereotactic radiotherapy different from normal radiotherapy?
Stereotactic radiotherapy delivers very precise, high doses of radiation directly to the tumour from many different angles, which helps spare surrounding healthy tissue.
Will I have to pay to take part?
No, you do not pay for clinical trial treatments in the UK. The trial drug and study-related tests are provided free of charge, and some travel expenses may be covered.
Can I leave the study if I change my mind?
Yes. You are free to leave the trial at any point, for any reason, and your regular medical team will continue to look after you.
Can I take my usual medications during the trial?
Some medicines might interact with the trial drug. You will need to share a complete list of everything you take with the study team so they can advise you safely.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.